Invisalign maker Align Technology cuts annual revenue forecast on weak demand

Align Technology (ALGN.O) shares fell sharply by approximately 30% in extended trading after the company significantly cut its 2025 annual revenue growth forecast to flat to slightly up, down from its prior range of 3.5% to 5.5%. This revised outlook is driven by macroeconomic uncertainties and reduced patient demand for elective dental procedures, impacting sales of its Invisalign aligners and iTero scanner systems. The company also reported Q2 revenue of $1.01 billion and adjusted EPS of $2.49, both missing analyst estimates, and provided Q3 revenue guidance below expectations. In response, Align plans workforce reductions and manufacturing optimization, anticipating $150 million to $170 million in one-time charges in the second half of 2025.

Analysis

Align Technology has signaled a significant deterioration in its business outlook, evidenced by a drastic cut in its 2025 annual revenue forecast from a growth range of 3.5%-5.5% to merely flat-to-slightly-up. This revision, which triggered a near 30% decline in its share price in extended trading, is attributed directly to macroeconomic pressures weakening consumer demand for elective procedures. The company's leadership explicitly cited lower patient traffic and hesitancy in orthodontic case starts as primary headwinds. The challenges are not just forward-looking; they are reflected in the company's second-quarter performance, where revenue of $1.01 billion and adjusted EPS of $2.49 both fell short of analyst estimates of $1.06 billion and $2.57, respectively. Furthermore, third-quarter revenue guidance of $965 million to $985 million points to continued weakness, with the midpoint falling well below the consensus estimate of $1.04 billion. In response, Align is initiating a significant restructuring that includes workforce reductions and manufacturing optimization, which is expected to incur one-time charges of $150 million to $170 million in the latter half of 2025, indicating a period of operational and financial adjustment ahead.

Key Decisions for Investors

• Investors should fundamentally reassess valuation models for ALGN, as the revised guidance from mid-single-digit growth to flat revenue invalidates prior growth assumptions.
• Given the weak consumer demand for elective procedures, monitor key industry metrics like patient traffic and orthodontic case starts for any signs of stabilization before considering the stock's discounted price.
• Factor in the execution risk and financial impact of the upcoming restructuring, including the $150-$170 million in one-time charges, which will pressure margins and profitability in the second half of 2025.
• Exercise caution in the near term, as the combination of a current earnings miss, weak forward guidance, and a sharp negative market reaction suggests significant downside momentum and heightened uncertainty.